

1 of 2

| | | | | | | | |
|---------------------------------|--|--|--|-----------------------|------------------------|------------------------|---------------------------------|
| Form PTO-1449 (Rev. 8-83) | | U.S. Department of Commerce Patent and Trademark Office | | Serial No. 826,809 | Group Art Unit 1646 | Filing Date 4-17-04 | Atty. Docket No. MSB-7273-D1 |
| INFORMATION DISCLOSURE CITATION | | | | Applicant(s) | Armen B. Shansfelt | | |

U.S. PATENT DOCUMENTS

| * | | DOCUMENT NO. | | | | | | | | DATE | NAME | CLASS | SUB-CLASS | FILING DATE IF APPROPRIATE | |
|---|--|--------------|--|--|--|--|--|--|--|------|------|-------|-----------|----------------------------|--|
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

FOREIGN PATENT DOCUMENTS


| * | | DOCUMENT NO. | | | | | | | | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION | | |
|----|---|--------------|---|---|---|---|---|---|----------|------|---------|-------|-----------|-------------|----|--|
| | | | | | | | | | | | | | | YES | NO | |
| PM | M | 0 | 2 | 6 | 7 | 7 | 9 | 5 | 05/18/88 | EP | C07K | 13/00 | | | | |
| PM | N | 0 | 1 | 6 | 3 | 2 | 4 | 9 | 12/04/85 | EP | C12N | 15/00 | | | X | |
| PM | O | 0 | 1 | 1 | 9 | 6 | 2 | 1 | 09/26/84 | EP | C12N | 15/00 | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|----|----|--|
| PM | S | Zurawski S.M. and Zurawski G., Receptor antagonist and selective agonist derivatives of mouse interleukin-2, Embo.J., 11(11): 3905-3910 (1992) |
| | T | Zurawski et al., Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeric receptor, Embo.J., 12(13): 5113-5119 (1993) |
| | U | Thèze et al., Interleukin 2 and its receptors: recent advances and new immunological functions, Immunol. Today, 17(10): 481-486 (1996) |
| | V | Xu et al., Biological and receptor-binding activities of human interleukin-2 mutated at residues 20Asp, 125Cys or 127Ser, Eur.Cytokine Netw., 6(4): 237-244 (1995) |
| | W | Jacobson et al., Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity, Proc.Natl.Sci., 93: 10405-10410 (1996) |
| | X | Smith K. A., Lowest Dose Interleukin-2 Immunotherapy, Blood, 81(6): 1414-1423 (1993) |
| | Y | Kaplan et al., Rational Immunotherapy with Interleukin 2, Biotech., 10(2): 157-162 (1992) |
| | Z | Buchli et al., Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog, Arch.Biochem. Biophys., 307(2): 411-415 (1993) |
| | AA | Cellular and Molecular Immunology, Abbas et al., eds., 1997, W.B. Saunders Company, Chapter 12, Cytokines, pp. 250-267 |
| ↓ | BB | Immunology, Roitt et al., eds., 1996, pp. 8.8-8.16, Fourth Edition, Mosby |

| | |
|--------------------------------|-----------------------------------|
| EXAMINER <i>Premma Menz</i> | DATE CONSIDERED <i>4/11/06</i> |
|--------------------------------|-----------------------------------|

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP section 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



2 of 2

| | | | | | |
|------------------------------|--|-------------------------|------------------------|------------------------|--------------------------------|
| Form PTO-1449 (Rev. 8-83) | U.S. Department of Commerce Patent and Trademark Office | Serial No. 10826,809 | Group Art Unit 1646 | Filing Date 4-17-04 | Atty. Docket No. MSB-7273-D |
|------------------------------|--|-------------------------|------------------------|------------------------|--------------------------------|

INFORMATION DISCLOSURE CITATION

Applicant(s) Armen B. Shanafelt

U.S. PATENT DOCUMENTS

| * | | DOCUMENT NO. | | | | | | | | DATE | NAME | CLASS | SUB-CLASS | FILING DATE IF APPROPRIATE |
|----|---|--------------|---|---|---|---|---|---|--|----------|-----------------|-------|-----------|----------------------------|
| PM | A | 5 | 6 | 9 | 6 | 2 | 3 | 4 | | 12/09/97 | Zurawski et al. | 530 | 351 | 08/01/94 |
| | B | 5 | 2 | 2 | 9 | 1 | 0 | 9 | | 07/20/93 | Grimm et al. | 424 | 85.2 | 04/14/92 |
| | C | 5 | 2 | 0 | 6 | 3 | 4 | 4 | | 04/27/93 | Katre et al. | 530 | 351 | 01/11/88 |
| | D | 5 | 1 | 1 | 6 | 9 | 4 | 3 | | 05/26/92 | Koths et al. | 530 | 351 | 05/10/88 |
| | E | 4 | 9 | 5 | 9 | 3 | 1 | 4 | | 09/25/90 | Mark et al. | 435 | 69.1 | 02/07/85 |
| | F | 4 | 8 | 5 | 3 | 3 | 3 | 2 | | 08/01/89 | Mark et al. | 435 | 252.33 | 12/21/84 |
| | G | 4 | 5 | 8 | 8 | 5 | 8 | 5 | | 05/13/86 | Mark et al. | 424 | 85 | 09/08/84 |
| ↓ | H | 4 | 5 | 1 | 8 | 5 | 8 | 4 | | 05/21/85 | Mark et al. | 424 | 85 | 12/20/83 |

FOREIGN PATENT DOCUMENTS:

| * | | DOCUMENT NO. | | | | | | | | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION | | |
|----|---|--------------|---|---|---|---|---|---|--|----------|---------|-------|-----------|-------------|----|--|
| | | | | | | | | | | | | | | YES | NO | |
| PM | I | 9 | 7 | 4 | 1 | 2 | 3 | 2 | | 11/06/97 | WO | C12N | 15/24 | | | |
| | J | 9 | 7 | 3 | 1 | 6 | 2 | 2 | | 09/04/97 | WO | A61K | 9/06 | | | |
| | K | 9 | 6 | 0 | 6 | 8 | 6 | 0 | | 03/07/96 | WO | C07K | 14/54 | | | |
| ↓ | L | 8 | 9 | 0 | 4 | 6 | 6 | 5 | | 06/01/89 | WO | A61K | 37/02 | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|----|---|---|
| PM | P | Zurawski, S.M. and Zurawski, G., Mouse interleukin-2 structure-function studies: substitutions in the first α -helix can specifically inactivate p70 receptor binding and mutations in the fifth α -helix can specifically inactivate p55 receptor binding, Embo.J., 8(9): 2583-2590 (1989) |
| | Q | Zurawski et al., Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction, Embo.J., 9(12): 3899-3905 (1990) |
| ↓ | R | Zurawski, G., Analysing lymphokine-receptor interactions of IL-1 and IL-2 by recombinant-DNA technology, Trends Biotech., 9: 250-257 (1991) |

EXAMINER

Prema Meny

DATE CONSIDERED

4/11/06

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP section 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.